LEXICON PHARMACEUTICALS, INC. (LXRX)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch LXRX
See up to 3 months of LXRX. The 7-day demo opens the 1M and 3M ranges and puts LXRX on your watchlist.
Start 7-day demoLatest LXRX insider trades
About LEXICON PHARMACEUTICALS, INC. (LXRX)
The SEC lists LEXICON PHARMACEUTICALS, INC. under CIK 0001062822, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
LXRX Form 4 activity by transaction type, last 90 days
No Form 4 activity for LXRX in the last 90 days.
LXRX insider transactions (Form 4)
8551 Form 4 filings on record, the earliest from Dec 2, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Judith L. Swain - Director | Option exercise | Common Stock | 89,312 | $0.00 | - | |
| Judith L. Swain - Director | Option exercise | Restricted Stock Units | 89,312 | $0.00 | - | |
 Diane E. Sullivan - Director | Option exercise | Common Stock | 89,312 | $0.00 | - | |
| Diane E. Sullivan - Director | Option exercise | Restricted Stock Units | 89,312 | $0.00 | - | |
| Christopher J. Sobecki - Director | Option exercise | Common Stock | 89,312 | $0.00 | - | |
| Christopher J. Sobecki - Director | Option exercise | Restricted Stock Units | 89,312 | $0.00 | - | |
 Ivan Cheung - Director | Option exercise | Common Stock | 89,312 | $0.00 | - | |
| Ivan Cheung - Director | Option exercise | Restricted Stock Units | 89,312 | $0.00 | - | |
| Sam L. Barker - Director | Option exercise | Common Stock | 89,312 | $0.00 | - | |
| Sam L. Barker - Director | Option exercise | Restricted Stock Units | 89,312 | $0.00 | - | |
| Philippe Amouyal - Director | Option exercise | Common Stock | 89,312 | $0.00 | - | |
| Philippe Amouyal - Director | Option exercise | Restricted Stock Units | 89,312 | $0.00 | - | |
| Raymond Debbane - Director | Option exercise | Common Stock | 89,312 | $0.00 | - | |
| Raymond Debbane - Director | Option exercise | Restricted Stock Units | 89,312 | $0.00 | - | |
| Participations S.A R.L. Artal | Option exercise | Common Stock | 20,421,735 | $0.00 | - | |
| Participations S.A R.L. Artal | Grant or award | Series B Convertible Preferred Stock | 408,435 | - footnote F1 | - | |
| Participations S.A R.L. Artal | Option exercise | Series B Convertible Preferred Stock | 408,435 | $0.00 | - | |
| ||||||
| Philippe Amouyal - Director | Grant or award | Restricted Stock Units | 35,714 | $0.00 | - | |
| Philippe Amouyal - Director | Grant or award | Stock Option (Right to Buy) | 43,478 | $0.00 | - | |
| Christopher J. Sobecki - Director | Grant or award | Restricted Stock Units | 35,714 | $0.00 | - | |
| Christopher J. Sobecki - Director | Grant or award | Stock Option (Right to Buy) | 43,478 | $0.00 | - | |
| Sam L. Barker - Director | Grant or award | Restricted Stock Units | 35,714 | $0.00 | - | |
| Sam L. Barker - Director | Grant or award | Stock Option (Right to Buy) | 43,478 | $0.00 | - | |
| Ivan Cheung - Director | Grant or award | Stock Option (Right to Buy) | 43,478 | $0.00 | - | |
| Ivan Cheung - Director | Grant or award | Restricted Stock Units | 35,714 | $0.00 | - | |
| Judith L. Swain - Director | Grant or award | Restricted Stock Units | 35,714 | $0.00 | - | |
| Judith L. Swain - Director | Grant or award | Stock Option (Right to Buy) | 43,478 | $0.00 | - | |
| Diane E. Sullivan - Director | Grant or award | Restricted Stock Units | 35,714 | $0.00 | - | |
| Diane E. Sullivan - Director | Grant or award | Stock Option (Right to Buy) | 43,478 | $0.00 | - | |
| Raymond Debbane - Director | Grant or award | Restricted Stock Units | 35,714 | $0.00 | - | |
| Raymond Debbane - Director | Grant or award | Stock Option (Right to Buy) | 43,478 | $0.00 | - | |
| Wendy McDermott - Officer | Option exercise | Common Stock | 27,697 | - footnote F1 | - | |
| Wendy McDermott - Officer | Option exercise | Common Stock | 52,316 | - footnote F1 | - | |
| Wendy McDermott - Officer | Option exercise | Common Stock | 144,393 | - footnote F1 | - | |
| Wendy McDermott - Officer | Tax withholding / forfeiture | Common Stock | 68,107 | $1.47 | $100K | |
| Wendy McDermott - Officer | Option exercise | Restricted Stock Units | 27,697 | - footnote F1 | - | |
| Wendy McDermott - Officer | Option exercise | Restricted Stock Units | 52,316 | - footnote F1 | - | |
| Wendy McDermott - Officer | Option exercise | Restricted Stock Units | 144,393 | - footnote F1 | - | |
| ||||||
 Rachel Yap Martens - Officer | Option exercise | Common Stock | 67,090 | - footnote F1 | - | |
| Rachel Yap Martens - Officer | Tax withholding / forfeiture | Common Stock | 35,826 | $1.47 | $53K | |
| Rachel Yap Martens - Officer | Option exercise | Restricted Stock Units | 67,090 | - footnote F1 | - | |
| ||||||
| Craig B. Granowitz - Officer | Option exercise | Common Stock | 35,790 | - footnote F1 | - | |
| Craig B. Granowitz - Officer | Option exercise | Common Stock | 74,226 | - footnote F1 | - | |
| Craig B. Granowitz - Officer | Option exercise | Common Stock | 202,260 | - footnote F1 | - | |
| Craig B. Granowitz - Officer | Tax withholding / forfeiture | Common Stock | 109,098 | $1.47 | $160K | |
| Craig B. Granowitz - Officer | Option exercise | Restricted Stock Units | 35,790 | - footnote F1 | - | |
| Craig B. Granowitz - Officer | Option exercise | Restricted Stock Units | 74,226 | - footnote F1 | - | |
| Craig B. Granowitz - Officer | Option exercise | Restricted Stock Units | 202,260 | - footnote F1 | - | |
| ||||||
 Suma Gopinathan - Officer | Option exercise | Common Stock | 14,000 | - footnote F1 | - | |
| Suma Gopinathan - Officer | Option exercise | Common Stock | 20,310 | - footnote F1 | - | |
| Suma Gopinathan - Officer | Option exercise | Common Stock | 65,640 | - footnote F1 | - | |
| Suma Gopinathan - Officer | Tax withholding / forfeiture | Common Stock | 24,338 | $1.47 | $36K | |
| Suma Gopinathan - Officer | Option exercise | Restricted Stock Units | 14,000 | - footnote F1 | - | |
| Suma Gopinathan - Officer | Option exercise | Restricted Stock Units | 20,310 | - footnote F1 | - | |
| Suma Gopinathan - Officer | Option exercise | Restricted Stock Units | 65,640 | - footnote F1 | - | |
| ||||||
| Lisa Defrancesco - Officer | Option exercise | Common Stock | 24,674 | - footnote F1 | - | |
| Lisa Defrancesco - Officer | Option exercise | Common Stock | 128,190 | - footnote F1 | - | |
| Lisa Defrancesco - Officer | Tax withholding / forfeiture | Common Stock | 74,572 | $1.47 | $110K | |
| Lisa Defrancesco - Officer | Option exercise | Restricted Stock Units | 24,674 | - footnote F1 | - | |
| Lisa Defrancesco - Officer | Option exercise | Restricted Stock Units | 128,190 | - footnote F1 | - | |
| ||||||
| Brian T. Crum - Officer | Option exercise | Common Stock | 33,457 | - footnote F1 | - | |
| Brian T. Crum - Officer | Option exercise | Common Stock | 69,386 | - footnote F1 | - | |
| Brian T. Crum - Officer | Option exercise | Common Stock | 170,163 | - footnote F1 | - | |
| Brian T. Crum - Officer | Tax withholding / forfeiture | Common Stock | 105,019 | $1.47 | $154K | |
| Brian T. Crum - Officer | Option exercise | Restricted Stock Units | 69,386 | - footnote F1 | - | |
| Brian T. Crum - Officer | Option exercise | Restricted Stock Units | 33,457 | - footnote F1 | - | |
| Brian T. Crum - Officer | Option exercise | Restricted Stock Units | 170,163 | - footnote F1 | - | |
| ||||||
| Scott M. Coiante - Officer | Option exercise | Common Stock | 160,237 | - footnote F1 | - | |
| Scott M. Coiante - Officer | Tax withholding / forfeiture | Common Stock | 54,881 | $1.47 | $81K | |
| Scott M. Coiante - Officer | Option exercise | Restricted Stock Units | 160,237 | - footnote F1 | - | |
| ||||||
 Michael Exton - Officer | Option exercise | Common Stock | 503,263 | - footnote F1 | - | |
| Michael Exton - Officer | Tax withholding / forfeiture | Common Stock | 204,831 | $1.47 | $301K | |
| Michael Exton - Officer | Option exercise | Restricted Stock Units | 503,263 | - footnote F1 | - | |
| ||||||
| Raymond Debbane - Director | Open-market purchase | Common Stock | 2,000 | $1.49 | $3K | |
| Raymond Debbane - Director | Open-market purchase | Common Stock | 100,000 | $1.47 | $147K | |
| Raymond Debbane - Director | Open-market purchase | Common Stock | 50,000 | $1.44 footnote F1 | $72K | |
| Raymond Debbane - Director | Open-market purchase | Common Stock | 100,000 | $1.48 footnote F2 | $148K | |
| ||||||
| Participations S.A R.L. Artal | Grant or award | Series B Convertible Preferred Stock | 41,290 | $65.00 | $2.68M | |
| Raymond Debbane - Director | Open-market purchase | Common Stock | 57,952 | $1.31 footnote F1 | $76K | |
| Raymond Debbane - Director | Open-market purchase | Common Stock | 76,857 | $1.31 footnote F2 | $101K | |
| Raymond Debbane - Director | Open-market purchase | Common Stock | 133,688 | $1.32 footnote F3 | $176K | |
| ||||||
| Wendy McDermott - Officer | Grant or award | Restricted Stock Units | 250,200 | $0.00 | - | |
| Wendy McDermott - Officer | Grant or award | Stock Option (Right to Buy) | 375,300 | $0.00 | - | |
| Rachel Yap Martens - Officer | Grant or award | Restricted Stock Units | 193,740 | $0.00 | - | |
| Rachel Yap Martens - Officer | Grant or award | Stock Option (Right to Buy) | 290,620 | $0.00 | - | |
Item 2.02, 9.01
Item 2.02, 9.01
Item 1.01, 2.03, 3.02, 7.01, 9.01
Item 2.02, 9.01
LXRX insider trading FAQ
What is the latest insider trade for LXRX?
LEXICON PHARMACEUTICALS, INC. (LXRX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-04. The full record for LXRX runs to 51 Form 4 filings, the earliest from 2024-12-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LXRX stock?
No insider purchases of LXRX were filed in the last 90 days. 8 purchases are on record for this company.
How many insiders are selling LXRX stock?
No insider sales of LXRX were filed in the last 90 days.
Where can I see LXRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LXRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Judith L. Swain view on EDGAR
- - Diane E. Sullivan view on EDGAR
- - Christopher J. Sobecki view on EDGAR
- - Ivan Cheung view on EDGAR
- - Sam L. Barker view on EDGAR
- - Philippe Amouyal view on EDGAR
- - Raymond Debbane view on EDGAR
- - Participations S.A R.L. Artal view on EDGAR
- - Philippe Amouyal view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where LXRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LXRX with a 7-day demo
- LXRX on your watchlist
- Every LXRX Form 4 filing on record
- Up to 3 months of LXRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
